Sangamo Therapeutics Inc
SGMO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$28.83M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $28.83 Million |
|---|---|
| Enterprise Value | $28.83 Million |
| Earnings per Share | $-0.44 |
| Beta | 1.3 |
| Outstanding Shares | 389,616,000 |
Return
| Return on Equity | -468187.69% |
|---|---|
| Return on Assets | -85789.41% |
| Return on Invested Capital | -87410.88% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.83 |
| Enterprise Value to EBIT | -0.23 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.04
Consensus analyst estimateRevenue Estimate
$14.67 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.67, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.6682▼ 2.84% |
|---|---|
| Total Calls | 365,600▼ 65.83% |
| Total Puts | 244,300▼ 67.22% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.14%▼ 26.91% |
|---|---|
| Total Invested | $29,040▼ 99.89% |
| Investors Holding | 7▼ 111.00% |
About Sangamo Therapeutics Inc
142 employees
CEO: Alexander Macrae
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The firm focuses on three therapeutic areas: inherited metabolic diseases, central nervous syste...